Macrolides

Type: Keyphrase

Name: Macrolides

First Reported Mar 08 2010 - Updated Mar 08 2010 - 1 Documents

Reportlinker Adds Global Anti-Infectives Industry

NEW YORK, March 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:http://www.reportlinker.com/p0181107/Global-Anti-Infectives-Industry.htmlThis report analyzes the worldwide markets for Anti-Infectives ... [Published Mar 08 2010 by Yahoo! Canada]

Entities: HIV/AIDS, Prevalence (Disease), Macrolides, Vaccine

First Reported Jan 07 2010 - Updated Jan 07 2010 - 1 Documents

Cipla Ltd

Reportlinker Adds Indian Pharmaceutical Market Outlook 2009-2024

See more news releases in: Computer Electronics, Multimedia & Internet, Publishing & Information Services, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Surveys, Polls and Research, Asian-related NewsNEW YORK, Jan. 7 /PRNewswire/ ... [Published Jan 07 2010 by PR Newswire]

Entities: India, Fluoroquinolones, Macrolides, Cipla Ltd, Cadila Healthcare Limited

First Reported Oct 14 2009 - Updated Oct 14 2009 - 1 Documents

Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics ... [Published Oct 14 2009 by BioPortfolio]

Entities: Antifungal, Bactericide, Antiviral

Quotes

Dr. Michael Flavin, Chairman and Chief Executive Officer of Advanced Life Sciences, commented: "We are excited about the opportunities that lie ahead in 2010 as we pursue a focused strategy to position Restanza, our once-daily, oral antibiotic, for success on two major fronts: community acquired bacterial pneumonia (CABP) and biodefense. We plan to continue to work with the U S FoodFood and Drug Administration (FDA) to complete a Special Protocol Assessment (SPA) that will lay the groundwork for initiating registration studies for development of Restanza in CABP. We are also continuing to work with Pfizer, our Asia-Pacific regional partner, on development and commercialization plans. In the area of biodefense, we plan to capitalize on our 2009 achievements, which included generating strong, positive data in four pivotal animal trials and receiving $3.8 million from the Department of Defense to study Restanza further as a potential broad-spectrum medical countermeasure. In 2010, we have an opportunity to secure additional non-dilutive capital through government development contracts which may also position us advantageously for procurement discussions with Department of Defense and Health and Human Services. We are also pursuing additional corporate partnerships as well as advancing additional formulations for hospital and pediatric indications with the goal of capturing the full value of the Restanza franchise." Full Year Expense Analysis, 2009 versus 2008:

Advanced Life Sciences Announces 2009 Fourth Quarter and Full Year ... [Ulitzer - Mar 11 2010]

Prabhavathi Fernandes, president and CEO of Cempra, said: "Bacterial pneumonia is a serious infection, particularly in the elderly population. Macrolides have been a mainstay of treatment for this and other indications but drug resistance has increased to more than 25% of clinical isolates. Doctors are looking for new and convenient alternatives and CEM-101 could be an important option. We look forward to advancing CEM-101 further into clinical development."

Cempra completes Phase I studies of antibiotic drug [Pharmacy Choice - Mar 11 2010]

Commented Dr. Flavin: "The goal of our biodefense program is to attract development funding from the U S Government that will ultimately lead to the acquisition of Restanza for the Strategic National Stockpile. The notice that we received from BARDA gives us confidence that we can attract additional development funding in the near term and the clearly defined regulatory pathway for the biodefense indications established with FDA will significantly increase our prospects for further development and acquisition contracts with the Department of Health and Human Services and the Department of Defense."

Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquir ... [TradingMarkets - Mar 11 2010]